Abstract

sCell-penetrating peptides (CPPs), also known as protein transduction domains, are a class of diverse amino acid sequences with the ability to cross cellular membranes. CPPs can deliver several bioactive cargos, including proteins, peptides, nucleic acids and chemotherapeutics, into cells. Ever since their discovery, synthetic and natural CPPs have been utilized in therapeutics delivery, gene editing and cell imaging in fundamental research and clinical experiments. Over the years, CPPs have gained significant attention due to their low cytotoxicity and high transduction efficacy. In the last decade, multiple investigations demonstrated the potential of CPPs as carriers for the delivery of therapeutics to treat various types of cancer. Besides their remarkable efficacy owing to fast and efficient delivery, a crucial benefit of CPP-based cancer treatments is delivering anticancer agents selectively, rather than mediating toxicities toward normal tissues. To obtain a higher therapeutic index and to improve cell and tissue selectivity, CPP-cargo constructions can also be complexed with other agents such as nanocarriers and liposomes to obtain encouraging outcomes. This review summarizes various types of CPPs conjugated to anticancer cargos. Furthermore, we present a brief history of CPP utilization as delivery systems for anticancer agents in the last decade and evaluate several reports on the applications of CPPs in basic research and preclinical studies.

Highlights

  • The results indicated higher levels of siVEGF internalization into human colon cancer cells and HeLa cells leading to a significant reduction in the intracellular

  • In the past few decades, much effort has been devoted to the discovery of novel cancer therapies

  • cell-penetrating peptides (CPPs) are receiving a great deal of attention due to their ability to deliver large cargos into numerous cancer cells

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Numerous studies have investigated the impact of implementing drug delivery systems, including viral-based vectors, nanoparticles and cell-penetrating peptides (CPPs), to improve cell penetration [4]. No CPPconjugated drug has yet been approved by the US Food and Drug Administration (FDA), and only a few have been evaluated in clinical trials [11] This might be attributable to some of the unfavorable characteristics of CPPs including low cytosolic delivery efficiency, susceptibility to proteolytic degradation, and the lack of selectivity for tumor cells and tissues [12,13]. Numerous investigations demonstrated that the conjugation between CPPs and nanoparticles is a potential delivery system in cancer cell-lines and cancer animal models [34]. We hope this review will contribute to the understanding of CPP-based anti-cancer drug delivery and guide the readership through the latest achievements made in this field

Challenges of Biomacromolecules and Chemotherapeutics Delivery
Delivery of Nucleic Acids
Delivery of Chemotherapeutics
Findings
Concluding Remarks and Future Perspectives
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call